July 17, 2023 03:32 PM EDT
AI
Pharma

EMA to drug de­vel­op­ers on AI: Car­ry out thor­ough risk as­sess­ments

Lia DeGroot

The EMA is urg­ing drug de­vel­op­ers to ap­pro­pri­ate­ly as­sess the risk of us­ing ar­ti­fi­cial in­tel­li­gence or ma­chine learn­ing in the drug de­vel­op­ment process and to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times